Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JRKN | ISIN: KYG0520K1094 | Ticker-Symbol: 2VJ
Tradegate
24.04.25
11:29 Uhr
0,735 Euro
+0,005
+0,68 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCLETIS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASCLETIS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7350,76512:50
0,7200,76012:49

Aktuelle News zur ASCLETIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAscletis sees no benefit to high, fast oral GLP-1 dose titration, takes low, slow regimen forward4
MiAscletis Pharma Reports Positive Phase Ib Results For ASC30 In Treating Obesity249BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30...
► Artikel lesen
MiAscletis Pharma Inc.: Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA28- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations...
► Artikel lesen
MiASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS OF U.S. PHASE IB MULTIPLE ASCENDING DOSE STUDY OF SMALL MOLECULE ...2
ASCLETIS PHARMA Aktie jetzt für 0€ handeln
17.04.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN4
09.04.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN5
01.04.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN2
31.03.ASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM ITS U.S. PHASE IB TRIAL WITH ASC30, A POTENTIALLY FIRST-IN-CLASS ...3
26.03.Ascletis slashes funding for former core programs in pivot to obesity7
26.03.ASCLETIS-B (01672): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE IN THE USE OF PROCEEDS2
13.03.ASCLETIS-B (01672): NOTICE OF BOARD MEETING2
12.03.Ascletis Announces Positive ASC47 Phase Ib Pharmacokinetic & Weight Loss Data From Australia Studies387BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia....
► Artikel lesen
12.03.Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide93ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively...
► Artikel lesen
12.03.ASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE IB STUDIES OF ASC47 MONOTHERAPY IN AUSTRALIA AND U.S. FDA ...2
19.02.Ascletis' swift surge into obesity continues with competitive oral GLP-1 data3
19.02.Ascletis Pharma Reports Positive Interim Phase 1b Data For ASC30 To Treat Obesity327BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) Wednesday reported positive interim results from the Phase 1b study of ASC30 for the treatment of obesity.The Phase Ib multiple ascending...
► Artikel lesen
19.02.Ascletis Pharma Inc.: Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30132- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) cohort 2 (weekly...
► Artikel lesen
19.02.ASCLETIS-B (01672): INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM FIRST TWO COHORTS OF U.S. PHASE IB MULTIPLE ASCENDING DOSE STUDY ...2
13.02.ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN1
03.02.ASCLETIS-B (01672): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 3, 2025-
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1